Tubuloside A, a phenylethanoid glycoside, alleviates diclofenac induced hepato‐nephro oxidative injury via Nrf2/HO‐1

The most prominent adverse effects of nonsteroidal anti‐inflammatory drugs (NSAIDs) such as diclofenac (DF) are hepato‐renal damage. Natural antioxidants can be preferred as an alternative and/or combination to improve this damage. This present study was conducted to evaluate the protective effect of Tubuloside A (TA) against diclofenac (DF)‐induced hepato‐renal damage. TA (1 mg/kg, ip) was administered to male Sprague–Dawley rats for 5 days, and DF (50 mg/kg, ip) was administered on Days 4 and 5. Plasma aspartate amino transferase, alanine amino transferase, alkaline phosphatase, blood urea nitrogen and creatinine were measured to evaluate liver and kidney functions. Additionally, oxidative stress parameters (malondialdehyde, glutathione, superoxide dismutase, catalase, and 8‐oxo‐7,8‐dihydro‐2′‐deoxyguanosine) in blood, liver, and kidney tissues, changes in mRNA expression of genes involved in the Nrf2/HO‐1 signalling pathway (Nrf2, HO‐1, NQO‐1, IL‐6, iNOS, Cox‐2, TNF‐α, IL1‐β and NFκB) and apoptotic process (Bcl‐2, Cas‐3 and Bax) in liver and kidney tissues were determined. Additionally, tissue sections were evaluated histopathologically. Biochemical, histopathological, and molecular results demonstrated the hepato‐renal toxic effects of DF, and TA treatment protected the liver and kidney from DF‐induced damage. This provides an explanation for the hepato‐nephro damage caused by DF and offers new ideas and drug targets together with TA for the prevention and treatment of DF injury.